SCHEMBL30862728

SCHEMBL30862728

O=C(Nc1ccc(C(F)(F)F)cc1)[C@H]1CCc2c(N3CCNCC3)c(=O)n3nc(-c4ccccc4)nc3n21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 4/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ BRD4 O60885 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ BRAF P15056 1/20 0.36
▸ F10 P00742 1/20 0.36
▸ MAPKAPK2 P49137 1/20 0.36
▸ OPRD1 P41143 1/20 0.35
▸ P2RY14 Q15391 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ SCN9A Q15858 1/20 0.35
▸ FPR1 P21462 1/20 0.35
▸ FPR2 P25090 1/20 0.35
▸ USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27386387 0.90 EPHX2 (0.39) TRPV1HDAC6BRD4JAK2JAK1
SCHEMBL27386866 0.90 EPHX2 (0.39) TRPV1HDAC6BRD4JAK2JAK1
SCHEMBL27386865 0.90 EPHX2 (0.39) TRPV1HDAC6BRD4JAK2JAK1
SCHEMBL30862713 0.86 WRN (0.41) TRPV1HDAC6JAK2JAK1LMNA
SCHEMBL30862683 0.86 WRN (0.41) TRPV1HDAC6JAK2JAK1LMNA
SCHEMBL30862847 0.86 WRN (0.41) TRPV1HDAC6JAK2JAK1LMNA
SCHEMBL30862689 0.85 HDAC6 (0.43) TRPV1HDAC6BRD4JAK2JAK1
SCHEMBL30862834 0.78 TRPV1 (0.44) TRPV1HDAC6BRD4JAK2JAK1
SCHEMBL30862836 0.76 WRN (0.46) TRPV1BRD4JAK2JAK1LMNA
SCHEMBL27386392 0.76 WRN (0.46) TRPV1BRD4JAK2JAK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601746-A1 TRICYCLIC COMPOUNDS AND THEIR USES Novartis AG (CH) 2025-08-20 — — EP disclosed
CN-120077048-A Tricyclic compounds and uses thereof 诺华股份有限公司 2025-05-30 — — CN disclosed
US-20240245694-A1 Tricyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-07-25 — — US disclosed
WO-2024079623-A1 TRICYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245694-A1 Tricyclic Compounds and their Uses F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R TRPV1 138/4885HDAC6 499/4885BRD4 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback